Great presentation by @maughanonc! SWOG S2200: cabozantinib + atezolizumab showed a PFS signal vs cabozantinib in metastatic papillary RCC (HR 0.46). Only 33 eligible patients after early closure for slow accrual. Small but important! #ESMO26 @oncoalert @myESMO